IDT Biologika
Dedicated to Contract Development and Manufacturing of
Viral Vaccines, Viral Vectors and Biologics

IDT Biologika specializes in the contract development and manufacturing of Viral Vaccines, Gene and Immunotherapeutics as well as sterile liquids and lyophilized Biologics. We help biopharmaceutical and biotech companies as well as the US government as part of research consortia with the challenging and complex process of translating viral vaccines and biopharmaceuticals from the research lab through clinical development to large-scale commercial manufacturing including drug substance production, fill & finish, packaging and analytics. IDT Biologika provides fully integrated services for GMP compliant end-to-end services in BSL2 facilities meeting EMA, FDA and ANVISA standards.

We strive for strong, trusting and enduring customer partnerships. Our almost 100 year tradition in manufacturing vaccines and biopharmaceuticals motivates and obligates us to advance our clients’ products to prevent and treat diseases that impact the health of people worldwide.

 

Our Awards

ViE Awards

Best Contract Manufacturing Organization
2021

CMO Leadership Award 2021

Service

CMO Leadership Award 2021

Reliability

PharmaTech Outlook

2020

Twitter
@IDT Biologika

Study with optimized vector vaccine MVA-SARS-2-S resumed

Monday, 19. July 2021

Optimized vector vaccine against corona shows good efficacy in preliminary tests. more info

Federal Minister of Health Jens Spahn and Prime Minister Reiner Haseloff visit IDT Biologika

Monday, 19. April 2021

Dessau-based company to now fill AstraZeneca COVID-19 vaccine - Merz Pharma is foregoing capacities at short notice more info

IDT Biologika lays foundations for new multifunctional vaccine production building

Thursday, 8. April 2021

Overall, a total of 100 million euros are currently being invested in the site... more info

IDT Biologika and Takeda support production of the Johnson & Johnson single-shot COVID-19 vaccine

Monday, 15. March 2021

Takeda provides booked capacity at the IDT site in Dessau more info

Start of second study phase of vector vaccine against COVID-19 postponed

Monday, 11. January 2021

Initial data for corona vaccine indicate good tolerability but weak immune response more info